The protein encoded by this gene forms a potassium channel that is thought to play a critical role in the regulation of neuronal excitability, particularly in sensory cells of the cochlea. The current generated by this channel is inhibited by M1 muscarinic acetylcholine receptors and activated by retigabine, a novel anti-convulsant drug. The encoded protein can form a homomultimeric potassium channel or possibly a heteromultimeric channel in association with the protein encoded by the KCNQ3 gene. Defects in this gene are a cause of nonsyndromic sensorineural deafness type 2, an autosomal dominant form of progressive hearing loss. Two transcript variants encoding different isoforms have been found for this gene.
DFNA 2; DFNA2; KCNQ 4; Kcnq4; KCNQ4_HUMAN; KQT like 4; KQT-like 4; KV7.4; Potassium channel KQT like 4; potassium channel KQT-like 4; Potassium channel subunit alpha KvLQT4; potassium channel, voltage gated KQT-like subfamily Q, member 4; Potassium voltage gated channel KQT like protein 4; Potassium voltage gated channel KQT like subfamily member 4; Potassium voltage gated channel subfamily KQT member 4; Potassium voltage-gated channel subfamily KQT member 4; potassium voltage-gated channel, KQT-like subfamily, member 4; potassium voltage-gated channel, subfamily Q, member 4; Voltage gated potassium channel subunit Kv7.4; Voltage-gated potassium channel subunit Kv7.4